A team of investigators sought to assess the efficacy and safety of cilostazol vs aspirin, both with and without probucol, a cholesterol-lowering agent, in Asian patients with ischemic stroke.
Only patients transported via EMS were enrolled, suggesting that these findings are limited to those with more severe blunt head injury vs those who self-present to the emergency department.
Although spot sign predicted ICH expansion, it proved to be a less robust diagnostic marker than demonstrated by previous single-center cohort studies.
Risk for symptomatic intracranial hemorrhage after endovascular treatment for acute ischemic stroke is significantly higher in real-world practice than rates reported by clinical trials.
Compared with other sources of ICH, those associated with arteriovenous malformations had lower odds of death.
Intracranial atherosclerosis was lower in patients with migraine compared with those without migraine.
Patients receiving treatment with vitamin K antagonists (VKA) or antiplatelet agents face a significantly increased risk of mortality within 24 hours of intracranial hemorrhage.
Concomitant use of oral anticoagulants contributed to a significantly higher increased risk for ICH.
The idea of low-dose tPA will likely not be abandoned despite recent findings.
Risk factors differ from ischemic stroke.
REVERSE-AD is an ongoing phase 3 cohort study evaluating the reversal effects of idarucizumab on dabigatran.
Treatment with IV tPA appeared safe and feasible with stroke onset confirmation from MRI.
Surprisingly, multiple types of stroke were associated with a greater risk of seizure than TBI.
Patients with symptoms of TIA should undergo brain imaging to rule out ICH prior to antithrombotic therapy.
The study did not establish whether early intervention improves outcomes.
Compared to standard treatment with IV tPA, endovascular thrombectomy resulted in better functional outcomes at 90 days.
Treatment of intracerebral hemorrhage after thrombolysis did not result in reduced mortality or expansion of the hematoma.
A simple blood test may indicate risk of intracerebral hemorrhage and post-stroke outcomes.
NOACs are prescribed to patients with lower stroke risk compared to those prescribed Warfarin.
Those treated with a stent were twice as likely to suffer a stroke or transient ischemic attack compared to those treated with medication alone.
Those taking dabigatran (Pradaxa) had higher risk of major bleeds, including gastrointestinal bleeding.
Neurology Advisor Articles
- OCD in Duchenne Muscular Dystrophy Features Distinct Phenotype, Associated Symptoms
- History of Migraine Associated With Higher Risk for Cochlear Disorders
- Patent Foramen Ovale Closure for Stroke Prevention: Key Principles for Clinical Practice
- Vagus Nerve Stimulation in Pediatric Epilepsy: Weighing the Risks and Benefits
- A Model for Predicting Quality of Life Improvements After Deep Brain Stimulation
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- Apomorphine Infusions Improves Off Time Associated With Parkinson Disease
- FDA Grants Orphan Drug Status to Angelman Syndrome Treatment
- Treatment of New-Onset Epilepsy: AAN, AES Update Practice Guidelines
- Clinical, Radiologic Markers Predictive of Cortical Superficial Siderosis in ICH Identified
- Migraine Pain Location May Not Have Clinical Implications